Dynamic Technology Lab Private Ltd Invests $1.13 Million in Catalent, Inc. (NYSE:CTLT)

Dynamic Technology Lab Private Ltd purchased a new stake in shares of Catalent, Inc. (NYSE:CTLT - Free Report) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 18,665 shares of the company's stock, valued at approximately $1,131,000.

A number of other institutional investors and hedge funds have also made changes to their positions in CTLT. Thurston Springer Miller Herd & Titak Inc. acquired a new position in Catalent during the 2nd quarter worth about $42,000. Sentry Investment Management LLC acquired a new stake in shares of Catalent during the third quarter worth about $53,000. Longfellow Investment Management Co. LLC boosted its stake in shares of Catalent by 45.7% in the second quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company's stock valued at $55,000 after purchasing an additional 305 shares during the period. GAMMA Investing LLC grew its holdings in shares of Catalent by 25.9% in the second quarter. GAMMA Investing LLC now owns 1,032 shares of the company's stock valued at $58,000 after purchasing an additional 212 shares in the last quarter. Finally, Intact Investment Management Inc. purchased a new stake in Catalent during the 3rd quarter worth approximately $73,000.

Catalent Stock Down 0.9 %

NYSE:CTLT opened at $60.76 on Wednesday. Catalent, Inc. has a 1 year low of $36.74 and a 1 year high of $61.50. The company has a quick ratio of 1.96, a current ratio of 2.51 and a debt-to-equity ratio of 1.38. The stock has a 50-day simple moving average of $59.83 and a 200-day simple moving average of $58.36.

Catalent (NYSE:CTLT - Get Free Report) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of $0.05 by ($0.18). The company had revenue of $1.02 billion during the quarter, compared to analysts' expectations of $1.06 billion. Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The business's revenue for the quarter was up 4.2% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.10) earnings per share. On average, equities analysts forecast that Catalent, Inc. will post 0.84 earnings per share for the current year.

Insider Buying and Selling

In other news, insider David Mcerlane sold 1,994 shares of the stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $59.97, for a total value of $119,580.18. Following the completion of the sale, the insider now directly owns 36,304 shares of the company's stock, valued at approximately $2,177,150.88. This represents a 5.21 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Michelle R. Ryan sold 2,800 shares of Catalent stock in a transaction on Monday, November 11th. The shares were sold at an average price of $59.70, for a total transaction of $167,160.00. Following the completion of the transaction, the director now directly owns 10,835 shares in the company, valued at $646,849.50. The trade was a 20.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 5,114 shares of company stock worth $305,931 in the last ninety days. 0.31% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on CTLT shares. Baird R W downgraded shares of Catalent from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, September 24th. William Blair restated a "market perform" rating on shares of Catalent in a report on Tuesday, September 3rd. StockNews.com cut Catalent from a "hold" rating to a "sell" rating in a research note on Friday, November 22nd. Finally, Robert W. Baird reaffirmed a "neutral" rating and issued a $63.50 target price on shares of Catalent in a report on Tuesday, September 24th. One analyst has rated the stock with a sell rating and seven have given a hold rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $63.40.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.